| This is a paid advertisement for SmartBrief readers. |
| The content does not necessarily reflect the view of SmartBrief or its Association partners. |
| |
| If you are having trouble viewing this message in your e-mail client, please see the web version here |
 | | |  | | | | | | | | | Clinical Trials: Safety First
Regulatory and public focus on adverse events is growing. A key differentiator for your drug is its safety profile – and understanding the landscape for your class of drugs is an imperative. Deriving insights across multiple trials for multiple indications is much faster with an aggregated approach. Intuitive analytics that draw together disparate trial data allow you to easily identify areas of interest or concern and compare drugs. Download this article to learn about new methods to assess drug safety in clinical trials, helping you quickly answer questions like: - Is the safety data on my drug sufficiently better than the current gold standard to warrant approval?
- Why is my competitor continuing with this drug candidate when reports of its efficacy aren't very encouraging?
- What adverse events are reported in the literature for a particular intervention or class of drugs?
| | | | | | | | | | | | |  | | |  | | | | 1500 Spring Garden Street, Fourth Floor, Philadelphia, PA 19130 USA
77 Hatton Garden, London EC1N 8JS, UK
Palaceside Bldg. 5F, 1-1-1 Hitotsubashi, Chiyoda-ku, Tokyo 100-0003 Japan
18 Science Park Drive,Singapore 118229
To ensure our emails reach your inbox, please add us to your address book.
Copyright © 2013 Thomson Reuters | | | | |
About this email: BIO SmartBrief will occasionally send emails from our advertising partners promoting products and services determined to be of interest and relevance to our readers. Each email is carefully considered on a case-by-case basis. If you do not want to receive these emails, you can unsubscribe from them by clicking here.
SmartBrief, Inc.® 555 11th ST NW, Suite 600, Washington, DC 20004 | |
No comments:
Post a Comment